Last updated: March 2026
M-Sten (Methylstenbolone / Ultradrol) is one of the most potent oral designer steroids ever sold as a "legal" supplement. With a 660:90 anabolic:androgenic ratio, it delivers dry, dense mass gains but carries severe hepatotoxicity from 17α-alkylation. Banned under DASCA 2014 — liver support is essential, not optional.
Unlike DMZ (which is a prodrug), M-Sten is a direct-acting anabolic-androgenic steroid. It binds androgen receptors directly without requiring in vivo conversion, delivering potent anabolic effects alongside significant hepatic stress from its 17α-alkylated structure.
M-Sten (2,17α-dimethyl-5α-androsta-1-en-17β-ol-3-one) is a direct-acting AAS, not a prodrug. The key structural features are the 17α-methyl group (enabling oral bioavailability), the 2-methyl substitution, and a 1-en double bond distinguishing it from Superdrol. It binds androgen receptors with high affinity and is not a substrate for aromatase, meaning it produces no estradiol conversion. This results in dry, hard muscle gains without water retention — the hallmark characteristic community users associate with M-Sten cycles.
The 17α-methyl group that gives M-Sten oral bioavailability also forces hepatic metabolism through cytochrome P450 pathways that generate reactive oxygen species and oxidative stress. This is the same mechanism responsible for hepatotoxicity across all 17α-alkylated oral steroids (Dianabol, Superdrol, Winstrol, etc.). M-Sten is widely considered among the most hepatotoxic oral compounds available in underground markets — community bloodwork consistently shows severe ALT/AST elevation even at low doses and short cycles. TUDCA + NAC are non-negotiable, not optional additions.
M-Sten does not aromatize to estradiol, which produces the characteristically dry, dense muscle appearance associated with the compound. Community comparisons to Superdrol are common, with many users reporting M-Sten as slightly superior for lean mass gain mg-for-mg. The absence of estrogenic activity means no water retention and no risk of gynecomastia from the compound itself, but also removes estrogen's cardioprotective benefit — making the lipid disruption profile particularly dangerous. HDL suppression during an M-Sten cycle is considered severe.
Like all AAS, M-Sten suppresses the hypothalamic-pituitary-testicular axis through androgen-mediated negative feedback. Elevated androgen signaling reduces GnRH pulsatility, suppresses LH and FSH secretion, and halts Leydig cell testosterone production during the cycle. Recovery of endogenous testosterone production after cycle completion requires post-cycle therapy (PCT) with SERMs such as tamoxifen (Nolvadex) or clomiphene (Clomid). Without PCT, testosterone recovery can take months. PCT is considered mandatory — not optional — in every harm-reduction framework for M-Sten use.
No human clinical trials exist for Methylstenbolone. All data below is derived from community bloodwork reports, anecdotal observations, and structural analysis. Source quality is explicitly noted — this is harm-reduction data, not clinical evidence.
M-Sten and Superdrol are frequently compared — both are potent oral designer steroids sold as legal supplements before DASCA 2014, both are highly hepatotoxic, and both produce dry, hard gains. But they are structurally distinct compounds with different profiles.
The key structural difference between M-Sten and Superdrol is a double bond at the 1-position in the M-Sten molecule. Superdrol is 2α,17α-dimethyl-5α-androstane-17β-ol-3-one; M-Sten is 2,17α-dimethyl-5α-androsta-1-en-17β-ol-3-one. This single structural difference gives M-Sten its slightly different pharmacological profile — higher anabolic ratio (660:90 vs Superdrol's reported ~400:20) and slightly different hepatic metabolism pathway, though both remain highly hepatotoxic through the 17α-alkylation mechanism.
Community consensus generally places M-Sten slightly above Superdrol for raw anabolic potency at equivalent doses. The 660:90 anabolic:androgenic ratio compares favorably to Superdrol's commonly cited 400:20 — meaning M-Sten is more anabolic and also carries more androgenic activity in absolute terms. Lean mass gains from M-Sten are widely described as dense and dry, comparable in quality to Superdrol but often reported as greater in magnitude at the same mg dose. Neither compound has clinical trial data to confirm these comparisons — all evidence is anecdotal.
Both M-Sten and Superdrol are 17α-alkylated and both produce severe hepatic stress. Community bloodwork reports place them in a similar tier of hepatotoxicity — both are considered "extreme" risk compounds requiring mandatory liver support. There is no clinical basis for claiming one is meaningfully safer than the other for the liver. TUDCA + NAC are required for both. Cycles exceeding 4 weeks are strongly discouraged for either compound. Stacking with any other 17α-alkylated oral is considered an extreme risk regardless of the combination.
The side effect profiles of M-Sten and Superdrol overlap substantially: hepatotoxicity, HDL suppression, lethargy, back pumps, HPTA suppression, and androgenic effects. M-Sten's slightly higher androgenic score (90 vs Superdrol's 20) may produce marginally more androgenic side effects in sensitive individuals. Both require PCT with SERMs and liver enzyme monitoring. The practical harm-reduction protocols for both compounds are nearly identical — the main difference is that M-Sten's higher anabolic ratio may tempt users to run higher doses, which amplifies all risk parameters proportionally.
Liver protection and monitoring are non-negotiable with M-Sten. These are the harm-reduction essentials — mandatory, not optional purchases for anyone considering this compound.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational and harm-reduction purposes only. M-Sten (Methylstenbolone / Ultradrol) is a Schedule III controlled substance in the United States under the Designer Anabolic Steroid Control Act (DASCA) of 2014. Possession, sale, or distribution without a valid prescription is a federal crime. No human clinical trials exist for Methylstenbolone. All human data is derived from anecdotal community reports and should not be interpreted as established medical fact. This content does not constitute medical advice. Always consult a licensed physician before using any anabolic agent. The harm-reduction information presented here is not an endorsement of use.